MCID: ADR005
MIFTS: 58

Adrenal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adrenal Carcinoma

MalaCards integrated aliases for Adrenal Carcinoma:

Name: Adrenal Carcinoma 12 36 15
Adrenal Cancer 12 73 20 54 70
Adrenal Gland Cancer 12 42 15
Malignant Neoplasm of Adrenal Gland 12 32
Adrenal Gland Neoplasms 44 70
Carcinoma of the Adrenal Gland 12
Tumor of the Adrenal Gland 12
Neoplasm of Adrenal Gland 12
Adrenocortical Carcinoma 70
Malignant Adrenal Tumor 12
Adrenal Gland Neoplasm 17
Adrenal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3950 DOID:3953
KEGG 36 H00033
ICD9CM 34 194.0
MeSH 44 D000310
NCIt 50 C2859 C9338
SNOMED-CT 67 127021009 93665005
ICD10 32 C74 C74.9
UMLS 70 C0001624 C0206686 C0750887

Summaries for Adrenal Carcinoma

GARD : 20 Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). There are three different types of adrenal cancer which vary by location and the age at which they are often diagnosed: Adrenocortical carcinoma - The most common type of adrenal cancer which develops in the adrenal cortex (the outer part of the adrenal gland) Neuroblastoma - A childhood cancer that begins in the adrenal medulla (the inner part of the adrenal gland) Pheochromocytoma - A neuroendocrine tumor that begins in the adrenal medulla The signs and symptoms associated with the condition largely depend on if the cancer is 'functioning' (producing hormones ) or 'nonfunctioning' (not producing hormones) and which hormones are present in excess. In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer. Treatment may include a combination of surgery, hormone therapy, chemotherapy and radiation therapy.

MalaCards based summary : Adrenal Carcinoma, also known as adrenal cancer, is related to adrenal neuroblastoma and gangliocytoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Cell cycle and Aldosterone synthesis and secretion. The drugs Etomidate and Iodine have been mentioned in the context of this disorder. Affiliated tissues include adrenal glands which are located above the kidneys, adrenal gland and thyroid, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An endocrine gland cancer located in the adrenal glands which are located above the kidneys.

MedlinePlus : 42 Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions. A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon. Types of tumors include Adrenocortical carcinoma - cancer in the outer part of the gland Neuroblastoma, a type of childhood cancer Pheochromocytoma - a rare tumor that is usually benign Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

KEGG : 36 Adrenocortical carcinoma (ACC) is a rare endocrine malignancy defined by a heterogeneous clinical presentation, dismal prognosis, and lack of effective therapeutic regimens. The incidence of ACC ranges from 0.5 to 2 cases per million people per year, accounting for 0.02% of all reported cancers. Unfortunately, most patients present with metastatic disease which reduces the 5 year survival rate to less than 10%. Oncogenes and tumor-suppressor genes involved in adrenal carcinomas include mutations in the p53 tumor-suppressor gene and rearrangements of the chromosomal locus 11p15.5 associated with IGF II hyperexpression. Deletions of the ACTH receptor gene have recently been found in undifferentiated adenomas and in aggressive ACCs.

Wikipedia : 73 An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of... more...

Related Diseases for Adrenal Carcinoma

Diseases related to Adrenal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 adrenal neuroblastoma 32.2 SYP ENO2
2 gangliocytoma 31.0 SYP POMC ENO2 CRH
3 small cell carcinoma 31.0 TP53 SYP ENO2
4 neuroendocrine carcinoma 30.8 SYP MEN1 ENO2
5 adrenal cortical carcinoma 30.8 TP53 SYP POMC NR5A1 MIR483 IGF2
6 neuroblastoma 30.7 TP53 SYP MEN1 IGF2 ENO2 CCND1
7 adrenogenital syndrome 30.6 SYP CYP21A2
8 leiomyosarcoma 30.5 TP53 MLANA IGF2 ENO2
9 amenorrhea 30.5 POMC NR5A1 CYP17A1 CRH
10 hypokalemia 30.4 REN POMC KCNJ5 CYP17A1 CYP11B1 CRH
11 conn's syndrome 30.3 REN POMC MEN1 KCNJ5 CYP21A2 CYP17A1
12 malignant pheochromocytoma 30.3 SYP MIR483 ENO2
13 hypoaldosteronism 30.2 REN POMC CYP11B2
14 neuroendocrine tumor 30.2 SYP POMC MEN1 ENO2
15 multiple endocrine neoplasia, type i 30.1 SYP POMC MIR483 MEN1
16 hyperinsulinemic hypoglycemia 30.1 MEN1 KCNJ5 IGF2 ENO2
17 pheochromocytoma 30.1 SYP REN POMC MEN1 IGF2 ENO2
18 lipoid congenital adrenal hyperplasia 30.0 REN POMC NR5A1 CYP21A2 CYP17A1 CYP11B2
19 premature menopause 30.0 TP53 POMC NR5A1 CYP21A2 CYP17A1
20 beckwith-wiedemann syndrome 30.0 TP53 MIR483 MEN1 IGF2
21 adenoma 29.8 TP53 SYP REN POMC MEN1 KCNJ5
22 adrenal cortical adenoma 29.6 SYP REN POMC NR5A1 MLANA MIR483
23 adrenal adenoma 29.6 REN POMC MIR483 MEN1 KCNJ5 IGF2
24 adrenal medulla cancer 11.1
25 adenomatoid tumor 10.6
26 malignant melanocytic neoplasm of the peripheral nerve sheath 10.5 SYP ENO2
27 anal neuroendocrine tumor 10.5 SYP ENO2
28 optic nerve astrocytoma 10.5 SYP ENO2
29 cerebral neuroblastoma 10.5 SYP ENO2
30 neuronal intestinal dysplasia, type b 10.5 SYP ENO2
31 lung meningioma 10.5 SYP ENO2
32 sinonasal undifferentiated carcinoma 10.5 SYP ENO2
33 autoimmune hepatitis type 2 10.5 CYP21A2 CYP17A1
34 auditory system benign neoplasm 10.5 SYP ENO2
35 papillary tumor of the pineal region 10.5 SYP ENO2
36 auditory system cancer 10.5 SYP ENO2
37 cloacogenic carcinoma 10.5 SYP ENO2
38 pineal region teratoma 10.5 SYP ENO2
39 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.5 SYP ENO2
40 cauda equina neoplasm 10.5 SYP ENO2
41 intracranial primitive neuroectodermal tumor 10.5 SYP ENO2
42 nodular prostate 10.5 SYP ENO2
43 ampulla of vater benign neoplasm 10.5 SYP ENO2
44 appendix carcinoid tumor 10.5 SYP ENO2
45 lymphocytic hypophysitis 10.5 POMC ENO2
46 penis sarcoma 10.5 MLANA ENO2
47 carotid body cancer 10.5 SYP ENO2
48 gallbladder small cell carcinoma 10.5 SYP ENO2
49 esophageal leukoplakia 10.5 TP53 CCND1
50 ureter small cell carcinoma 10.5 SYP ENO2

Graphical network of the top 20 diseases related to Adrenal Carcinoma:



Diseases related to Adrenal Carcinoma

Symptoms & Phenotypes for Adrenal Carcinoma

UMLS symptoms related to Adrenal Carcinoma:


fever; flank pain

GenomeRNAi Phenotypes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCND1 CYP11B1 CYP21A2 IGF2 KCNJ5 MEN1

MGI Mouse Phenotypes related to Adrenal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.17 CCNB1 CCND1 CRH CYP11B1 CYP17A1 CYP21A2
2 growth/size/body region MP:0005378 10.03 CCND1 CRH CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 cardiovascular system MP:0005385 10 CCND1 CYP11B1 CYP11B2 CYP17A1 IGF2 KCNJ5
4 nervous system MP:0003631 9.73 CCND1 CRH CYP11B2 ENO2 GRN IGF2
5 renal/urinary system MP:0005367 9.28 CCNB1 CRH CYP11B1 CYP11B2 GRN IGF2

Drugs & Therapeutics for Adrenal Carcinoma

Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etomidate Approved Phase 3 33125-97-2 36339 667484
2
Iodine Approved, Investigational Phase 3 7553-56-2 807
3
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
4
Mitotane Approved Phase 3 53-19-0 4211
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Cadexomer iodine Experimental Phase 3 94820-09-4
10 Anesthetics Phase 3
11 Hypnotics and Sedatives Phase 3
12 Anesthetics, General Phase 3
13 Anesthetics, Intravenous Phase 3
14 Tubulin Modulators Phase 3
15 Antimitotic Agents Phase 3
16 Dermatologic Agents Phase 3
17 Podophyllotoxin Phase 3 518-28-5
18 Keratolytic Agents Phase 3
19 Antineoplastic Agents, Hormonal Phase 3
20 Anti-Bacterial Agents Phase 3
21 Etoposide phosphate Phase 3
22
Liposomal doxorubicin Phase 3 31703
23 Antibiotics, Antitubercular Phase 3
24
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
25
Lactitol Approved, Investigational Phase 2 585-86-4 157355
26
acetic acid Approved Phase 2 64-19-7 176
27
Sodium citrate Approved, Investigational Phase 2 68-04-2
28
Tamoxifen Approved Phase 2 10540-29-1 2733526
29
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
32
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
33
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
34
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
35
Ipilimumab Approved Phase 2 477202-00-9
36
Pembrolizumab Approved Phase 2 1374853-91-4
37
nivolumab Approved Phase 2 946414-94-4
38
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
39
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
41
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
42
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
43 Gossypol Investigational Phase 2 303-45-7
44
Suramin Investigational Phase 2 145-63-1 5361
45 Adrenocorticotropic Hormone Phase 2
46 Liver Extracts Phase 2
47 Retinol palmitate Phase 2
48 retinol Phase 2
49 Gossypol acetic acid Phase 2
50
Retinol acetate Phase 2 127-47-9 10245972

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
2 Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia Unknown status NCT02010957 Phase 3
3 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Unknown status NCT00777244 Phase 3 MITOTANE
4 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation Completed NCT00997594 Phase 2, Phase 3
5 Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening Completed NCT00037843 Phase 3 I-131 Iodocholesterol
6 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
7 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
9 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
10 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Active, not recruiting NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
11 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
12 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
13 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
14 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
15 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
16 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
17 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
18 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
19 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
20 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
23 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
24 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
25 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
26 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
27 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
28 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Recruiting NCT04187404 Phase 1, Phase 2
29 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
30 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
31 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
32 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
33 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
34 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
35 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
36 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
37 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
38 Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies Not yet recruiting NCT04785287 Phase 1, Phase 2
39 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
40 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
41 Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
42 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
43 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
44 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
45 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
46 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
47 A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications Completed NCT01772004 Phase 1 Avelumab
48 Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59) Completed NCT00591643 Phase 1
49 A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
50 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin

Search NIH Clinical Center for Adrenal Carcinoma

Cochrane evidence based reviews: adrenal gland neoplasms

Genetic Tests for Adrenal Carcinoma

Anatomical Context for Adrenal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Carcinoma:

19
Adrenal Glands Which Are Located Above The Kidneys

MalaCards organs/tissues related to Adrenal Carcinoma:

40
Adrenal Gland, Thyroid, Cortex, Adrenal Cortex, Pituitary, Kidney, Lung

Publications for Adrenal Carcinoma

Articles related to Adrenal Carcinoma:

(show top 50) (show all 873)
# Title Authors PMID Year
1
Laparoscopic transperitoneal adrenalectomy in the large adrenal tumor from single center experience. 42
33522915 2021
2
Determinants of anxiety and depression among pheochromocytoma patients: A case-control study. 42
33546066 2021
3
Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma. 42
33138083 2020
4
The modification and expression of 21-hydroxylase gene in normal human adrenal gland and adrenal cancer. 54 61
1687042 1991
5
Suspicious adrenal incidentaloma in a patient with Congenital Adrenal Hyperplasia: A case report. 61
33511036 2021
6
Prostatic tissue in 46XX congenital adrenal hyperplasia: Case report and literature review. 61
33768909 2021
7
Diagnostic value of positron-emission tomography textural indices for malignancy of 18F-fluorodeoxyglucose-avid adrenal lesions. 61
30916534 2021
8
Cancer risk in adrenalectomy: are adrenal lesions equal or more than 4 cm a contraindication for laparoscopy? 61
33650006 2021
9
β-catenin in adrenal zonation and disease. 61
33338548 2021
10
[A Case of Adrenal Anastomosing Hemangioma]. 61
33535290 2021
11
Delaying Cancer Cases in Urology during COVID-19: Review of the Literature. 61
32692934 2020
12
[French ccAFU guidelines - update 2020-2022: malignancy assessment of an adrenal incidentaloma]. 61
33349429 2020
13
Disseminated nocardiosis with adrenal abscess masquerading as metastatic adrenal cancer in an immunocompetent adult. 61
33137243 2020
14
Robotic and Laparoscopic Approaches for Adrenal Surgery in Obese Patients. 61
33131284 2020
15
Laparoscopic Right Adrenalectomy in a Large Right Adrenal Oncocytic Carcinoma. 61
33244737 2020
16
Development of an index of complexity for outpatient endocrinology and nutrition clinics. 61
32507700 2020
17
Uncommon tumors in multiple endocrine neoplasia (MEN) type 1: Do they have a relationship with the prognosis of these patients? 61
32909176 2020
18
Etomidate infusion at low doses is an effective and safe treatment for severe Cushing's syndrome outside intensive care. 61
32449698 2020
19
[The no-need-to-see process for adrenal incidentalomas]. 61
33000724 2020
20
The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study. 61
32560605 2020
21
CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension. 61
31089198 2020
22
Adrenal angiosarcoma with metastasis: Imaging and histopathology of a rare adrenal cancer. 61
32123554 2020
23
Bilateral adrenal histoplasmosis presenting as adrenal insufficiency in an immunocompetent host in the Philippines. 61
32404324 2020
24
Two giant retroperitoneal schwannomas mimicking adrenal malignancy - a case report. 61
33506097 2020
25
Three-year follow up of adrenal incidentalomas in a New Zealand centre. 61
31058434 2020
26
A Man with a Clot on his Platelets: Adrenal Carcinoma and Dynamic Right Ventricular Inflow Obstruction. 61
31442387 2020
27
Are Adrenal Lesions of 6 cm or More in Diameter a Contraindication to Laparoscopic Adrenalectomy? A Case-Control Study. 61
31728629 2020
28
From ACTH-Dependent to ACTH-Independent Cushing's Syndrome from a Malignant Mixed Corticomedullary Adrenal Tumor: Potential Role of Embryonic Stem Cells. 61
32426170 2020
29
Smoking is associated with adrenal adenomas and adrenocortical carcinomas: a nationwide multicenter analysis. 61
32871402 2020
30
Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line. 61
33133015 2020
31
Nomograms for the Prediction of Survival for Patients with Pediatric Adrenal Cancer after Surgery. 61
32127935 2020
32
[An Uncommon Cause of Arterial Hypertension]. 61
32456579 2020
33
Adrenal tumours: open surgery versus minimally invasive surgery. 61
31644473 2020
34
Primary extragonadal yolk sac tumor originating from adrenal gland. 61
31860425 2019
35
Successful treatment of metastatic adrenocortical carcinoma in the spine: A case report and literature review. 61
31804360 2019
36
Fairly rare small-diameter hepatocellular carcinoma with right adrenal gland metastasis having an inferior vena cava tumor thrombus: a case report. 61
31696344 2019
37
Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study. 61
31717612 2019
38
Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma. 61
31169262 2019
39
Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group. 61
31109814 2019
40
Review and Comparison of Computational Approaches for Joint Longitudinal and Time-to-Event Models. 61
32042217 2019
41
Right atrial and ventricular invasion by adrenal carcinoma: A case report. 61
31440309 2019
42
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. 61
31234202 2019
43
[A Case of WDHA Water Diarrhea Hypokalemia Achlorhydria Syndrome that Developed after Multimodal Therapy for Retroperitoneal Paraganglioma]. 61
31501391 2019
44
Metastatic Carcinomas of the Adrenal Glands: From Diagnosis to Treatment. 61
31177104 2019
45
Erythrocytosis as the first manifestation of adrenal carcinoma. 61
30859743 2019
46
Adrenal tumors: when to search for a germline abnormality? 61
30985498 2019
47
[Adrenal carcinoma with vena cava thrombus]. 61
30758566 2019
48
Hypertensive choroidopathy and adrenal carcinoma: A new association. 61
30337095 2019
49
ADRENAL CARCINOMA IN CHILDREN: LONGITUDINAL STUDY IN MINAS GERAIS, BRAZIL. 61
30066822 2019
50
Evaluating the effectiveness of computed tomography-guided 125I seed interstitial implantation in patients with secondary adrenal carcinoma. 61
31436236 2019

Variations for Adrenal Carcinoma

Cosmic variations for Adrenal Carcinoma:

9 (show top 50) (show all 118)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88301868 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 40
2 COSM90654925 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 40
3 COSM88294143 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 40
4 COSM90652830 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.373G>T p.V125F 3:10149819-10149819 40
5 COSM88293303 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 40
6 COSM88288959 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 40
7 COSM88296074 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 40
8 COSM88292246 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 40
9 COSM90652721 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.368A>G p.Q123R 3:10149814-10149814 40
10 COSM88292324 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 40
11 COSM90657160 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 40
12 COSM88305342 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 40
13 COSM90653943 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>G p.K118E 3:10149798-10149798 40
14 COSM90668341 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.369G>T p.Q123H 3:10149815-10149815 40
15 COSM88292236 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 40
16 COSM90652730 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 40
17 COSM90648957 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.359G>A p.R120Q 3:10149805-10149805 40
18 COSM90664073 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.341-3225T>G p.? 3:10146562-10146562 40
19 COSM90811579 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 40
20 COSM92347003 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 40
21 COSM142343426 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1289+3268T>C p.? 10:43114500-43114500 40
22 COSM142343204 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.*102T>C p.? 10:43121968-43121968 40
23 COSM92347226 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 40
24 COSM90811811 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 40
25 COSM93530486 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 40
26 COSM93656552 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.G629R 17:31225134-31225134 40
27 COSM93692982 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 40
28 COSM93650970 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
29 COSM120509060 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
30 COSM93535461 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 40
31 COSM109968573 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 40
32 COSM109960979 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
33 COSM93512112 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.G629R 17:31225134-31225134 40
34 COSM93508888 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40
35 COSM93509879 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.? 17:31227607-31227607 40
36 COSM120509488 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40
37 COSM93507010 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7237C>T p.Q2413* 17:31349230-31349230 40
38 COSM93662933 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 40
39 COSM93654948 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 40
40 COSM93504734 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.? 17:31221932-31221932 40
41 COSM93507162 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
42 COSM120515658 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 40
43 COSM93650764 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 40
44 COSM93517207 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7519C>T p.Q2507* 17:31352381-31352381 40
45 COSM109960306 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1724A>T p.Y575F 17:31221932-31221932 40
46 COSM93652933 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40
47 COSM93668028 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 40
48 COSM93647950 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.? 17:31221932-31221932 40
49 COSM93688082 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 40
50 COSM109961525 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40

Expression for Adrenal Carcinoma

Search GEO for disease gene expression data for Adrenal Carcinoma.

Pathways for Adrenal Carcinoma

GO Terms for Adrenal Carcinoma

Biological processes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.85 TP53 REN CRH CCND1 CCNB1
2 steroid metabolic process GO:0008202 9.73 CYP21A2 CYP17A1 CYP11B2 CRH
3 regulation of blood pressure GO:0008217 9.67 REN POMC CYP11B1
4 negative regulation of telomerase activity GO:0051974 9.55 TP53 MEN1
5 C21-steroid hormone biosynthetic process GO:0006700 9.54 CYP11B2 CYP11B1
6 cellular response to potassium ion GO:0035865 9.52 CYP11B2 CYP11B1
7 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 CCND1
8 mineralocorticoid biosynthetic process GO:0006705 9.48 CYP21A2 CYP11B2
9 sterol metabolic process GO:0016125 9.43 CYP21A2 CYP11B2 CYP11B1
10 cortisol biosynthetic process GO:0034651 9.4 CYP11B2 CYP11B1
11 cortisol metabolic process GO:0034650 9.37 CYP11B2 CYP11B1
12 cellular response to peptide hormone stimulus GO:0071375 9.33 MEN1 CYP11B2 CYP11B1
13 aldosterone biosynthetic process GO:0032342 9.32 CYP11B2 CYP11B1
14 steroid biosynthetic process GO:0006694 9.26 CYP21A2 CYP17A1 CYP11B2 CYP11B1
15 glucocorticoid biosynthetic process GO:0006704 8.92 CYP21A2 CYP17A1 CYP11B2 CYP11B1

Molecular functions related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.67 CYP21A2 CYP17A1 CYP11B2 CYP11B1
2 iron ion binding GO:0005506 9.62 CYP21A2 CYP17A1 CYP11B2 CYP11B1
3 corticosterone 18-monooxygenase activity GO:0047783 9.26 CYP11B2 CYP11B1
4 monooxygenase activity GO:0004497 9.26 CYP21A2 CYP17A1 CYP11B2 CYP11B1
5 steroid 11-beta-monooxygenase activity GO:0004507 9.16 CYP11B2 CYP11B1
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.92 CYP21A2 CYP17A1 CYP11B2 CYP11B1

Sources for Adrenal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....